Physician profile
Mark C Gottron
NPI 1093713968
$18,982.11
in general payments reported to CMS, 2019-2025
56 companies · $2,369 in 2025
The $2,369 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,962 · 2020: $2,381 · 2021: $3,889 · 2022: $2,661 · 2023: $2,247 · 2024: $2,473 · 2025: $2,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,090.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,089.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,728.23 | 2019-2025 | |
| Novo Nordisk INC | $2,339.38 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $2,130.42 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $1,009.94 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $981.12 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $892.09 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $868.47 | 2019-2023 | Xarelto |
| Allergan, INC. | $698.29 | 2019-2020 | |
| Amarin Pharma, INC. | $601.80 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $591.78 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $537.15 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $525.30 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $522.65 | 2021-2025 | |
| Abbott Laboratories | $491.78 | 2021-2025 | Proclaim, Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $479.63 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gottron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.